Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Randomized, Double-Blinded and Placebo-Controlled Study Evaluating the Efficacy and Safety of 0.25% HBM9036 (HL036) Ophthalmic Solution Compared to Placebo in Chinese Subjects With Moderate and Severe Dry Eye

NCT04633213 is registered in ClinicalTrials.gov with Harbour BioMed (Guangzhou) Co. Ltd. as lead sponsor.

NCT NCT04633213
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04633213 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Randomized, Double-Blinded and Placebo-Controlled Study Evaluating the Efficacy and Safety of 0.25% HBM9036 (HL036) Ophthalmic Solution Compared to Placebo in Chinese Subjects With Moderate and Severe Dry Eye
Lead sponsor
Harbour BioMed (Guangzhou) Co. Ltd.
Phase
Phase 3
Overall status
Completed
Start date
February 25, 2021
Completion date
August 7, 2022
Enrollment
577 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dry eye